P: (303) 772-3300 | F: (303) 682-3380 | M-F 7:30am – 5:30pm

For Physicians/Co-Management

Eye Care Center of Northern Colorado is one of Colorado’s most advanced facilities for eye health, surgery and vision correction. We have invested in the latest eye care technologies to bring you state-of-the-art eye surgery procedures.

We strive to consistently meet or exceed the service and patient care expectation of our patients. We do so by investing in staff education and new treatment modalities. We maintain a convenient, comfortable, warm, and pleasant environment to our patients. We make it a priority to be available and accessible to both the patient as well as to referring doctors. We welcome hearing from you any time about questions regarding your patients’ care. We are available to you!

For URGENT referrals, please call our office directly at (303) 772-3300.

Option 2 is the Priority Physician Line for faster service.

Please FAX non-urgent referrals to
303-682-3380

Clinical Trials

Unity / UBX1325-02

ClinicalTrials.gov Identifier: NCT04857996

A Phase 2a, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema

Detailed Description

This is a Phase 2a Proof-of-Concept (POC) study. The study will enroll approximately 62 patients randomized 1:1 into either the UBX1325 or sham study arms, in order to assess the primary objective. All patients will be followed for approximately 24 weeks.

Inclusion Criteria

  • Patients aged ≥ 18 years.
  • Diabetic retinopathy patients (nonproliferative (NPDR) and proliferative (PDR)) with DME (ETDRS-DRSS Score at 65C [or DR severity level of 8] or less severe), who had at least one of 3 anti-VEGF agents: aflibercept, bevacizumab or ranibizumab in the preceding 6 months prior to Day 1, with the last anti-VEGF given between 3 and 6 weeks prior to Day 1.
  • Center-involved DME with central subfield thickness (CST) ≥350 µm on SD-OCT at Screening
  • BCVA in the study eye (most affected) of 70 to 20 ETDRS letters (equivalent to 20/40 to 20/400 on the Snellen chart) at Screening and at Day 1.
    Exclusion Criteria
    • Concurrent disease in the study eye or structural damage, other than DME, that could compromise BCVA, prevent BCVA improvement, require medical or surgical intervention during the study period, confound interpretation of the results, or interfere with assessment of toxicity or color fundus photography (CFP) in the study eye.
    • High risk/active PDR, defined as: any vitreous or preretinal hemorrhage, neovascularization elsewhere >1/2 disc area within an area equivalent to standard ETDRS 7-field on clinical examination, or neovascularization of disc >1/3 disc area on clinical examination
    • Any ocular/intraocular/periocular infection or inflammation in either eye
    • History of vitreous hemorrhage in the study eye within 2 months prior to Screening
    • Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation or prevent the patient from fully participating in all aspects of the study
    • Significant media opacities, including cataract, which might interfere with VA, assessment of toxicity, or fundus imaging

    Opthea / OPT-302-1004

    ClinicalTrials.gov Identifier: NCT04757610

    A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD

    Brief Summary

    A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

    Inclusion Criteria
    • Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
    • An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.
    Exclusion Criteria
    • Any previous treatment for neovascular AMD.
    • Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
    • Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.

    Education

    Continuing education provided by the physicians of Eye Care Center of Northern Colorado.